Concorde Asset Management, LLC Anixa Biosciences Inc Transaction History
Concorde Asset Management, LLC
- $159 Million
- Q2 2024
A detailed history of Concorde Asset Management, LLC transactions in Anixa Biosciences Inc stock. As of the latest transaction made, Concorde Asset Management, LLC holds 13,969 shares of ANIX stock, worth $44,002. This represents 0.02% of its overall portfolio holdings.
Number of Shares
13,969Holding current value
$44,002% of portfolio
0.02%Shares
7 transactions
Others Institutions Holding ANIX
# of Institutions
53Shares Held
5.5MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.39MShares$4.39 Million0.0% of portfolio
-
D.A. Davidson & Co.736KShares$2.32 Million0.01% of portfolio
-
Laird Norton Trust Company, LLC604KShares$1.9 Million0.19% of portfolio
-
Ubs Group Ag531KShares$1.67 Million0.0% of portfolio
-
Mission Wealth Management, LP502KShares$1.58 Million0.03% of portfolio
About Anixa Biosciences Inc
- Ticker ANIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,661,700
- Market Cap $96.6M
- Description
- Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the...